Evidence map›Paper›PMID 39702187›Full record

ArticleHereditary cancer in clinical practice2024

BRCA2 germline mutation carrier with five malignancies: a case report.

Elena Su, Yann Christinat, Thomas McKee, Silvia Azzarello-Burri, Wolfram Jochum, Stefanie Fischer, Christian Rothermundt

Abstract read
In one paragraph

Article in Hereditary cancer in clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elena SuDepartment of Gynecology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, St. Gallen, 9007, Switzerland.
Yann ChristinatDepartment of Clinical Pathology, Geneva University Hospitals, Rue Gabrielle-Perret- Gentil 4, Geneva, 1206, Switzerland.
Thomas McKeeAurigen SA, Avenue de Sévelin 18, Lausanne, 1004, Switzerland.
Silvia Azzarello-BurriInstitute of Pathology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, St. Gallen, 9007, Switzerland.
Wolfram JochumInstitute of Pathology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, St. Gallen, 9007, Switzerland.
Stefanie FischerDepartment of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, St. Gallen, 9007, Switzerland.
Christian RothermundtDepartment of Medical Oncology, Cantonal Hospital Lucerne, Spitalstrasse 16, Lucerne, 6000, Switzerland. christian.rothermundt@luks.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBRCA2 germline mutations are known to predispose carriers to various cancer types, including breast, ovarian, pancreatic and prostate cancer. An association with melanoma has also been reported. However, the full tumour spectrum associated with BRCA2 mutations, particularly in patients with other concurrent pathogenetic mutations, is unexplored. CASE PRESENTATION: We present a 70-year-old female patient with a pathogenic BRCA2 c.5946del variant. Over a period of 15 years, she has developed two independent breast cancers, well-differentiated liposarcoma, clear cell renal cell carcinoma and myeloproliferative neoplasia. This unusual tumour spectrum and the staggered occurrence of these tumours required multiple rounds of genetic testing and led to a delayed diagnosis of the BRCA2-associated tumour predisposition. In addition to the BRCA2 mutation, extended germline testing revealed an APC c.3920T > A variant and variants of unknown significance in the BRIP1 and ATR genes. The molecular analysis of the tumours revealed distinct profiles with differences in HRD status and in copy number variations, indicating no common origin.

conclusionsOur case study revealed that the pathogenic BRCA2 c.5946del germline variant can be associated with an unusual tumour spectrum, which may lead to a delayed diagnosis of a hereditary tumour predisposition. Thus, upfront genetic testing using large multigene panels or whole-genome sequencing in encouraged, especially in cases with a prominent family history.

Indexed as

APCBRCA2 mutationBreast cancerGenetic testingLiposarcomaMyeloproliferative neoplasiaRenal cell carcinomaWhole-genome sequencing

Identifiers

PMID39702187
PMCPMC11660894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.